Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H16N4O3 |
| Molecular Weight | 288.3018 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 2 |
SHOW SMILES / InChI
SMILES
O\N=C\C1=CC=[N+](COC[N+]2=CC=C(C=C2)\C=N\O)C=C1
InChI
InChIKey=HIGRLDNHDGYWQJ-UHFFFAOYSA-P
InChI=1S/C14H14N4O3/c19-15-9-13-1-5-17(6-2-13)11-21-12-18-7-3-14(4-8-18)10-16-20/h1-10H,11-12H2/p+2
Obidoxime is an antidote for organophosphorous nerve agent poisoning including chlorosarin, cyclosarin (GF), R-33 (VR), R-VX, sarin (GB), tabun (GA), VX, chlorosoman, soman (GD), and organophosphorous pesticides. It acts as an acetylcholinesterase (AChE) reactivator. In combination with atropine obidoxime can be used to treat super toxic organophosphate poisoning by relieving the symptoms of skeletal neuromuscular blocking that occurs during a cholinergic crisis.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66880
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
||
|
WHO-VATC |
QV03AB13
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
||
|
WHO-ATC |
V03AB13
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB14676MIG
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
OBIDOXIME
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
DB13750
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
7683-36-5
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
DTXSID50227649
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
100000080007
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
4676
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
8251
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
N6KNE1QA9O
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
C84023
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | |||
|
42826
Created by
admin on Mon Mar 31 18:47:38 GMT 2025 , Edited by admin on Mon Mar 31 18:47:38 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
